期刊
JOURNAL OF CONTROLLED RELEASE
卷 97, 期 3, 页码 503-511出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2004.04.003
关键词
desmopressin; transdermal delivery; coated microneedle array; pharmacokinetics; hairless guinea pig
Desmopressin is a synthetic peptide hormone chiefly used for treatment of enuresis in young children. It is available in injectable, intranasal, and oral formulations. While administration by injection is poorly suited for routine use in young children, intranasal and oral administration result in low and variable bioavailability. This study therefore explored the feasibility of administering desmopressin transdermally using Macroflux(R) technology, which uses a microneedle array to overcome the skin barrier. The tips of microneedles in 2-cm(2) arrays were covered with a solid coating of various arnounts of desmopressin and applied to the skin of hairless guinea pigs for 5 or 15 min. Pharmacologically relevant amounts of desmopressin were delivered after 5 min. Bioavailability was as high as 85% and showed acceptable variability (30%). Immunoreactive serum desmopressin reached peak levels after a T-max of 60 min. Elimination kinetics for serum desmopressin was similar after transdermal and intravenous (IV) delivery, suggesting the absence of a skin depot. Only 10% of the desmopressin dose loaded onto the microneedle array was found on the skin surface after application. Additionally, the patches were well tolerated. These results suggest that transdermal delivery of desmopressin by Macroflux(R) is a safe and efficient alternative to currently available routes of administration. (C) 2004 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据